The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hemoglobinopathy Market Research Report 2025
Synopsis
Hemoglobinopathies are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and/or synthesis of hemoglobin. Hemoglobinopathies are genetic single-gene disorders that lead to an abnormal structure of one of the globin chains of the hemoglobin molecule, rendering it unable to carry oxygen through the body, which leads to anemia or other medical abnormalities. The most common hemoglobinopathies are sickle cell disease, alpha thalassemia, and beta thalassemia.
The global Hemoglobinopathy market was valued at US$ 270 million in 2023 and is anticipated to reach US$ 368.1 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hemoglobinopathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathy.
Report Scope
The Hemoglobinopathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemoglobinopathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemoglobinopathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Diagnostics
Bio-Rad Laboratories
Danaher Corporation
Mindray Medical International
Nexcelom Bioscience
Nihon Kohden
PerkinElmer
Siemens Healthineers
Sysmex Corporation
Segment by Type
Sickle Cell Disease
Alpha Thalassemia
Beta Thalassemia
Segment by Application
Hospitals
Diagnostic Laboratories
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemoglobinopathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hemoglobinopathies are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and/or synthesis of hemoglobin. Hemoglobinopathies are genetic single-gene disorders that lead to an abnormal structure of one of the globin chains of the hemoglobin molecule, rendering it unable to carry oxygen through the body, which leads to anemia or other medical abnormalities. The most common hemoglobinopathies are sickle cell disease, alpha thalassemia, and beta thalassemia.
The global Hemoglobinopathy market was valued at US$ 270 million in 2023 and is anticipated to reach US$ 368.1 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hemoglobinopathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathy.
Report Scope
The Hemoglobinopathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemoglobinopathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemoglobinopathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Diagnostics
Bio-Rad Laboratories
Danaher Corporation
Mindray Medical International
Nexcelom Bioscience
Nihon Kohden
PerkinElmer
Siemens Healthineers
Sysmex Corporation
Segment by Type
Sickle Cell Disease
Alpha Thalassemia
Beta Thalassemia
Segment by Application
Hospitals
Diagnostic Laboratories
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemoglobinopathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemoglobinopathy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Sickle Cell Disease
1.2.3 Alpha Thalassemia
1.2.4 Beta Thalassemia
1.3 Market by Application
1.3.1 Global Hemoglobinopathy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostic Laboratories
1.3.4 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemoglobinopathy Market Perspective (2019-2030)
2.2 Hemoglobinopathy Growth Trends by Region
2.2.1 Global Hemoglobinopathy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hemoglobinopathy Historic Market Size by Region (2019-2024)
2.2.3 Hemoglobinopathy Forecasted Market Size by Region (2025-2030)
2.3 Hemoglobinopathy Market Dynamics
2.3.1 Hemoglobinopathy Industry Trends
2.3.2 Hemoglobinopathy Market Drivers
2.3.3 Hemoglobinopathy Market Challenges
2.3.4 Hemoglobinopathy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemoglobinopathy Players by Revenue
3.1.1 Global Top Hemoglobinopathy Players by Revenue (2019-2024)
3.1.2 Global Hemoglobinopathy Revenue Market Share by Players (2019-2024)
3.2 Global Hemoglobinopathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemoglobinopathy Revenue
3.4 Global Hemoglobinopathy Market Concentration Ratio
3.4.1 Global Hemoglobinopathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathy Revenue in 2023
3.5 Hemoglobinopathy Key Players Head office and Area Served
3.6 Key Players Hemoglobinopathy Product Solution and Service
3.7 Date of Enter into Hemoglobinopathy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemoglobinopathy Breakdown Data by Type
4.1 Global Hemoglobinopathy Historic Market Size by Type (2019-2024)
4.2 Global Hemoglobinopathy Forecasted Market Size by Type (2025-2030)
5 Hemoglobinopathy Breakdown Data by Application
5.1 Global Hemoglobinopathy Historic Market Size by Application (2019-2024)
5.2 Global Hemoglobinopathy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hemoglobinopathy Market Size (2019-2030)
6.2 North America Hemoglobinopathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hemoglobinopathy Market Size by Country (2019-2024)
6.4 North America Hemoglobinopathy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemoglobinopathy Market Size (2019-2030)
7.2 Europe Hemoglobinopathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hemoglobinopathy Market Size by Country (2019-2024)
7.4 Europe Hemoglobinopathy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathy Market Size (2019-2030)
8.2 Asia-Pacific Hemoglobinopathy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hemoglobinopathy Market Size by Region (2019-2024)
8.4 Asia-Pacific Hemoglobinopathy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemoglobinopathy Market Size (2019-2030)
9.2 Latin America Hemoglobinopathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hemoglobinopathy Market Size by Country (2019-2024)
9.4 Latin America Hemoglobinopathy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathy Market Size (2019-2030)
10.2 Middle East & Africa Hemoglobinopathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hemoglobinopathy Market Size by Country (2019-2024)
10.4 Middle East & Africa Hemoglobinopathy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Diagnostics
11.1.1 Abbott Diagnostics Company Detail
11.1.2 Abbott Diagnostics Business Overview
11.1.3 Abbott Diagnostics Hemoglobinopathy Introduction
11.1.4 Abbott Diagnostics Revenue in Hemoglobinopathy Business (2019-2024)
11.1.5 Abbott Diagnostics Recent Development
11.2 Bio-Rad Laboratories
11.2.1 Bio-Rad Laboratories Company Detail
11.2.2 Bio-Rad Laboratories Business Overview
11.2.3 Bio-Rad Laboratories Hemoglobinopathy Introduction
11.2.4 Bio-Rad Laboratories Revenue in Hemoglobinopathy Business (2019-2024)
11.2.5 Bio-Rad Laboratories Recent Development
11.3 Danaher Corporation
11.3.1 Danaher Corporation Company Detail
11.3.2 Danaher Corporation Business Overview
11.3.3 Danaher Corporation Hemoglobinopathy Introduction
11.3.4 Danaher Corporation Revenue in Hemoglobinopathy Business (2019-2024)
11.3.5 Danaher Corporation Recent Development
11.4 Mindray Medical International
11.4.1 Mindray Medical International Company Detail
11.4.2 Mindray Medical International Business Overview
11.4.3 Mindray Medical International Hemoglobinopathy Introduction
11.4.4 Mindray Medical International Revenue in Hemoglobinopathy Business (2019-2024)
11.4.5 Mindray Medical International Recent Development
11.5 Nexcelom Bioscience
11.5.1 Nexcelom Bioscience Company Detail
11.5.2 Nexcelom Bioscience Business Overview
11.5.3 Nexcelom Bioscience Hemoglobinopathy Introduction
11.5.4 Nexcelom Bioscience Revenue in Hemoglobinopathy Business (2019-2024)
11.5.5 Nexcelom Bioscience Recent Development
11.6 Nihon Kohden
11.6.1 Nihon Kohden Company Detail
11.6.2 Nihon Kohden Business Overview
11.6.3 Nihon Kohden Hemoglobinopathy Introduction
11.6.4 Nihon Kohden Revenue in Hemoglobinopathy Business (2019-2024)
11.6.5 Nihon Kohden Recent Development
11.7 PerkinElmer
11.7.1 PerkinElmer Company Detail
11.7.2 PerkinElmer Business Overview
11.7.3 PerkinElmer Hemoglobinopathy Introduction
11.7.4 PerkinElmer Revenue in Hemoglobinopathy Business (2019-2024)
11.7.5 PerkinElmer Recent Development
11.8 Siemens Healthineers
11.8.1 Siemens Healthineers Company Detail
11.8.2 Siemens Healthineers Business Overview
11.8.3 Siemens Healthineers Hemoglobinopathy Introduction
11.8.4 Siemens Healthineers Revenue in Hemoglobinopathy Business (2019-2024)
11.8.5 Siemens Healthineers Recent Development
11.9 Sysmex Corporation
11.9.1 Sysmex Corporation Company Detail
11.9.2 Sysmex Corporation Business Overview
11.9.3 Sysmex Corporation Hemoglobinopathy Introduction
11.9.4 Sysmex Corporation Revenue in Hemoglobinopathy Business (2019-2024)
11.9.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
